Watanabe N, Niitsu Y, Yamauchi N, Ohtsuka Y, Sone H, Neda H, Maeda M, Urushizaki I
Department of Internal Medicine, Sapporo Medical College, Japan.
Immunopharmacol Immunotoxicol. 1988;10(1):117-27. doi: 10.3109/08923978809014406.
A synergistic increase in the cytotoxic effects of recombinant human tumor necrosis factor (rH-TNF) and anti-cancer drugs was demonstrated in vitro. The cytotoxicity of rH-TNF against L-M cells in combination with Mitomycin C (MMC), Adriamycin (ADM), Cytosine arabinoside (Ara-C), Actinomycin D (ACD), Daunomycin (DM), Cisplatin (CDDP), Vincristine (VCR), and 5-Fluorouracil (5FU), based on the concentration necessary for 50% inhibition of cell growth (IC50), was 4 to 347 times as high as that of rH-TNF alone. The results suggest that combination therapy including rH-TNF and anti-cancer drugs may be of value in the treatment of malignancy in human patients.
体外实验证明,重组人肿瘤坏死因子(rH-TNF)与抗癌药物联合使用时,细胞毒性作用呈协同增强。基于半数抑制细胞生长所需浓度(IC50),rH-TNF与丝裂霉素C(MMC)、阿霉素(ADM)、阿糖胞苷(Ara-C)、放线菌素D(ACD)、柔红霉素(DM)、顺铂(CDDP)、长春新碱(VCR)及5-氟尿嘧啶(5FU)联合使用时对L-M细胞的细胞毒性,是rH-TNF单独使用时的4至347倍。结果表明,包含rH-TNF与抗癌药物的联合疗法可能对人类恶性肿瘤患者的治疗具有价值。